Azenta Mixed Performance: Growth in Multiomics Amid US Market Challenges Leads to TD Cowen Hold

TD Cowen's Brendan Smith has given his Hold rating due to a combination of factors affecting Azenta’s performance. The company has shown positive growth in certain areas, such as a notable increase in Multiomics revenue, particularly in the European and Chinese markets. This growth has been driven by strong sequencing volume and gene synthesis, which has helped offset weaknesses in other segments.

However, despite these positive developments, there are concerns that temper the overall outlook. The slowdown in spending within the US market, partly due to macroeconomic factors and government shutdowns, has impacted Azenta’s SMS revenue. Additionally, while restructuring efforts are expected to improve EBITDA margins, the overall revenue growth guidance for FY26 remains modest. These mixed signals contribute to the Hold rating, as the potential for growth is balanced by significant challenges.

https://www.tipranks.com/news/ratings/azentas-mixed-performance-growth-in-multiomics-amidst-us-market-challenges-leads-to-hold-rating-ratings